Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05360732 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 13, 2025 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Sep 1, 2025 to Sep 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v8
  2. Site contact updatedv7
  3. Primary completion date: Sep 1, 2024 to Sep 1, 2025v6
  4. Primary completion date: Sep 1, 2023 to Sep 1, 2024
    • Study completion date: Sep 1, 2024 to Sep 1, 2025
    v5
  5. Primary completion date: Sep 1, 2022 to Sep 1, 2023
    • Study completion date: Sep 1, 2023 to Sep 1, 2024
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 4, 2022 to Apr 22, 2022
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi- centered two-stage Pilot Study assessing the tolerability and toxicity of an alternating regimen of FOLFOX and FOLFIRI for the treatment of newly diagnosed and untreated metastatic pancreatic cancer in patients over the age of 65 years.
Trial Details
NCT Number NCT05360732
Lead Sponsor Fox Chase Cancer Center
Conditions
(from sponsor)		 Metastatic Pancreatic Cancer
Related terms Pancreatic Neoplasms
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov